-transparent.png){kind=logo}
The effects of ticlopidine (T) (500 mg daily) on platelet function were investigated in a double-blind placebo-controlled study in 38 middle-aged men with stable incapacitating angina pectoris. The in vitro platelet reactivity to aggregating agents, the platelet sensitivity to prostacyclin and the plasma levels of platelet specific proteins and fibrinogen were determined before and after 4 and 8 weeks of treatment. T exerted a potent inhibitory effect on ADP-and collagen-induced platelet aggregation. The effect of T was proportional to the pretreatment reactivity to ADP and collagen. The inhibitory effect of T on the epinephrine response was less pronounced. The plasma levels of beta-thromboglobulin, platelet factor 4 and fibrinogen were not influenced by T. The platelet inhibition of prostacyclin was potentiated by T, and it was demonstrated that T and prostacyclin had synergistic inhibitory effects on platelet aggregation.
U Berglund, and
H von Schenck, and
L Wallentin
January 1987,
European heart journal,
U Berglund, and
H von Schenck, and
L Wallentin
January 1985,
Advances in prostaglandin, thromboxane, and leukotriene research,
U Berglund, and
H von Schenck, and
L Wallentin
April 1991,
Arquivos brasileiros de cardiologia,
U Berglund, and
H von Schenck, and
L Wallentin
March 2007,
European journal of pharmacology,
U Berglund, and
H von Schenck, and
L Wallentin
September 2007,
Nihon rinsho. Japanese journal of clinical medicine,
U Berglund, and
H von Schenck, and
L Wallentin
October 1991,
The American journal of cardiology,
U Berglund, and
H von Schenck, and
L Wallentin
May 1997,
European heart journal,
U Berglund, and
H von Schenck, and
L Wallentin
August 1996,
Thrombosis and haemostasis,
U Berglund, and
H von Schenck, and
L Wallentin
April 2000,
Current treatment options in cardiovascular medicine,
U Berglund, and
H von Schenck, and
L Wallentin
June 2000,
Ugeskrift for laeger,
